Sinus Bradycardia: Normal Phenomenon Or Risk Factor? Evaluation Based on Recent Evidence Edison F
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Guidelines on the Diagnosis and Management of Pericardial
European Heart Journal (2004) Ã, 1–28 ESC Guidelines Guidelines on the Diagnosis and Management of Pericardial Diseases Full Text The Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology Task Force members, Bernhard Maisch, Chairperson* (Germany), Petar M. Seferovic (Serbia and Montenegro), Arsen D. Ristic (Serbia and Montenegro), Raimund Erbel (Germany), Reiner Rienmuller€ (Austria), Yehuda Adler (Israel), Witold Z. Tomkowski (Poland), Gaetano Thiene (Italy), Magdi H. Yacoub (UK) ESC Committee for Practice Guidelines (CPG), Silvia G. Priori (Chairperson) (Italy), Maria Angeles Alonso Garcia (Spain), Jean-Jacques Blanc (France), Andrzej Budaj (Poland), Martin Cowie (UK), Veronica Dean (France), Jaap Deckers (The Netherlands), Enrique Fernandez Burgos (Spain), John Lekakis (Greece), Bertil Lindahl (Sweden), Gianfranco Mazzotta (Italy), Joa~o Morais (Portugal), Ali Oto (Turkey), Otto A. Smiseth (Norway) Document Reviewers, Gianfranco Mazzotta, CPG Review Coordinator (Italy), Jean Acar (France), Eloisa Arbustini (Italy), Anton E. Becker (The Netherlands), Giacomo Chiaranda (Italy), Yonathan Hasin (Israel), Rolf Jenni (Switzerland), Werner Klein (Austria), Irene Lang (Austria), Thomas F. Luscher€ (Switzerland), Fausto J. Pinto (Portugal), Ralph Shabetai (USA), Maarten L. Simoons (The Netherlands), Jordi Soler Soler (Spain), David H. Spodick (USA) Table of contents Constrictive pericarditis . 9 Pericardial cysts . 13 Preamble . 2 Specific forms of pericarditis . 13 Introduction. 2 Viral pericarditis . 13 Aetiology and classification of pericardial disease. 2 Bacterial pericarditis . 14 Pericardial syndromes . ..................... 2 Tuberculous pericarditis . 14 Congenital defects of the pericardium . 2 Pericarditis in renal failure . 16 Acute pericarditis . 2 Autoreactive pericarditis and pericardial Chronic pericarditis . 6 involvement in systemic autoimmune Recurrent pericarditis . 6 diseases . 16 Pericardial effusion and cardiac tamponade . -
Cardiac Involvement in COVID-19 Patients: a Contemporary Review
Review Cardiac Involvement in COVID-19 Patients: A Contemporary Review Domenico Maria Carretta 1, Aline Maria Silva 2, Donato D’Agostino 2, Skender Topi 3, Roberto Lovero 4, Ioannis Alexandros Charitos 5,*, Angelika Elzbieta Wegierska 6, Monica Montagnani 7,† and Luigi Santacroce 6,*,† 1 AOU Policlinico Consorziale di Bari-Ospedale Giovanni XXIII, Coronary Unit and Electrophysiology/Pacing Unit, Cardio-Thoracic Department, Policlinico University Hospital of Bari, 70124 Bari, Italy; [email protected] 2 AOU Policlinico Consorziale di Bari-Ospedale Giovanni XXIII, Cardiac Surgery, Policlinico University Hospital of Bari, 70124 Bari, Italy; [email protected] (A.M.S.); [email protected] (D.D.) 3 Department of Clinical Disciplines, School of Technical Medical Sciences, University of Elbasan “A. Xhuvani”, 3001 Elbasan, Albania; [email protected] 4 AOU Policlinico Consorziale di Bari-Ospedale Giovanni XXIII, Clinical Pathology Unit, Policlinico University Hospital of Bari, 70124 Bari, Italy; [email protected] 5 Emergency/Urgent Department, National Poisoning Center, Riuniti University Hospital of Foggia, 71122 Foggia, Italy 6 Department of Interdisciplinary Medicine, Microbiology and Virology Unit, University of Bari “Aldo Moro”, Piazza G. Cesare, 11, 70124 Bari, Italy; [email protected] 7 Department of Biomedical Sciences and Human Oncology—Section of Pharmacology, School of Medicine, University of Bari “Aldo Moro”, Policlinico University Hospital of Bari, p.zza G. Cesare 11, 70124 Bari, Italy; [email protected] * Correspondence: [email protected] (I.A.C.); [email protected] (L.S.) † These authors equally contributed as co-last authors. Citation: Carretta, D.M.; Silva, A.M.; D’Agostino, D.; Topi, S.; Lovero, R.; Charitos, I.A.; Wegierska, A.E.; Abstract: Background: The widely variable clinical manifestations of SARS-CoV2 disease (COVID-19) Montagnani, M.; Santacroce, L. -
J Wave Syndromes
Review Article http://dx.doi.org/10.4070/kcj.2016.46.5.601 Print ISSN 1738-5520 • On-line ISSN 1738-5555 Korean Circulation Journal J Wave Syndromes: History and Current Controversies Tong Liu, MD1, Jifeng Zheng, MD2, and Gan-Xin Yan, MD3,4 1Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular disease, Department of Cardiology, Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin, 2Department of cardiology, The Second Hospital of Jiaxing, Jiaxing, China, 3Lankenau Institute for Medical Research and Lankenau Medical Center, Wynnewood, Pennsylvania, USA, 4The First Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, China The concept of J wave syndromes was first proposed in 2004 by Yan et al for a spectrum of electrocardiographic (ECG) manifestations of prominent J waves that are associated with a potential to predispose affected individuals to ventricular fibrillation (VF). Although the concept of J wave syndromes is widely used and accepted, there has been tremendous debate over the definition of J wave, its ionic and cellular basis and arrhythmogenic mechanism. In this review article, we attempted to discuss the history from which the concept of J wave syndromes (JWS) is evolved and current controversies in JWS. (Korean Circ J 2016;46(5):601-609) KEY WORDS: Brugada syndrome; Sudden cardiac death; Ventricular fibrillation. Introduction History of J wave and J wave syndromes The concept of J wave syndromes was first proposed in 2004 The J wave is a positive deflection seen at the end of the QRS by Yan et al.1) for a spectrum of electrocardiographic (ECG) complex; it may stand as a distinct “delta” wave following the QRS, manifestations of prominent J waves that are associated with a or be partially buried inside the QRS as QRS notching or slurring. -
The Syndrome of Alternating Bradycardia and Tachycardia by D
Br Heart J: first published as 10.1136/hrt.16.2.208 on 1 April 1954. Downloaded from THE SYNDROME OF ALTERNATING BRADYCARDIA AND TACHYCARDIA BY D. S. SHORT From the National Heart Hospita. Received September 15, 1953 Among the large number of patients suffering from syncopal attacks who attended the National Heart Hospital during a four-year period, there were four in whom examination revealed sinus bradycardia alternating with prolonged phases of auricular tachycardia. These patients presented a difficult problem in treatment. Each required at least one admission to hospital and in one case the symptoms were so intractable as to necessitate six admissions in five years. Two patients had mitral valve disease, one of them with left bundle branch block. One had aortic valve sclerosis while the fourth had no evidence of heart disease. THE HEART RATE The sinus rate usually lay between 30 and 50 a minute, a rate as slow as 22 a minute being observed in one patient (Table I). Sinus arrhythmia was noted in all four patients, wandering of TABLE I http://heart.bmj.com/ RATE IN SINus RHYTHM AND IN AURICULAR TACHYCARDIA Rate in Case Age Sex Associated Rate in auricular tachycardia heart disease sinus rhythm Auricular Venliicular 1 65 M Aortic valve sclerosis 28-48 220-250 60-120 2 47 F Mitral valve disease 35-75 180-130 90-180 on September 26, 2021 by guest. Protected copyright. 3 38 F Mitral valve disease 22-43 260 50-65 4 41 F None 35-45 270 110 the pacemaker in three, and periods of sinus standstill in two (Fig. -
Screening for Peripheral Artery Disease and Cardiovascular Disease Risk Assessment with Ankle Brachial Index in Adults the U.S
Understanding Task Force Recommendations Screening for Peripheral Artery Disease and Cardiovascular Disease Risk Assessment with Ankle Brachial Index in Adults The U.S. Preventive Services Task Force (Task The Task Force reviewed the use of ABI to screen for Force) has issued a final recommendation statement PAD and to predict a person’s risk of heart attacks on Screening for Peripheral Artery Disease (PAD) and stroke. The final recommendation statement and Cardiovascular Disease (CVD) Risk Assessment summarizes what the Task Force learned about with Ankle Brachial Index (ABI) in Adults. the potential benefits and harms of this screening: There is not enough evidence to judge the benefits This final recommendation statement applies to and harms of using ABI for this purpose. adults who do not have signs or symptoms of PAD and who have not been diagnosed with PAD, CVD, This fact sheet explains the recommendation and severe chronic kidney disease, or diabetes. what it might mean for you. PAD is a disease in which fatty deposits called plaque build up in What is peripheral the arteries, especially those in the legs. Over time, the plaque can block the flow of blood to the legs often artery disease? leading to pain with walking. What is Cardiovascular disease affects the heart and blood vessels. It is caused by a build up of plaque in arteries that supply the heart, brain, and cardiovascular other parts of the body. When the build up is in the legs it is called disease? PAD. Heart attacks and strokes are other common types of CVD. Facts About CVD and PAD Cardiovascular disease is the leading killer of both men and women in the United States. -
Cardiovascular Disease and Rehab
EXERCISE AND CARDIOVASCULAR ! CARDIOVASCULAR DISEASE Exercise plays a significant role in the prevention and rehabilitation of cardiovascular diseases. High blood pressure, high cholesterol, diabetes and obesity can all be positively affected by an appropriate and regular exercise program which in turn benefits cardiovascular health. Cardiovascular disease can come in many forms including: Acute coronary syndromes (coronary artery disease), myocardial ischemia, myocardial infarction (MI), Peripheral artery disease and more. Exercise can improve cardiovascular endurance and can improve overall quality of life. If you have had a cardiac event and are ready to start an appropriate exercise plan, Cardiac Rehabilitation may be the best option for you. Please call 317-745-3580 (Danville Hospital campus), 317-718-2454 (YMCA Avon campus) or 317-456-9058 (Brownsburg Hospital campus) for more information. SAFETY PRECAUTIONS • Ask your healthcare team which activities are most appropriate for you. • If prescribed nitroglycerine, always carry it with you especially during exercise and take all other medications as prescribed. • Start slow and gradually progress. If active before event, fitness levels may be significantly lower – listen to your body. A longer cool down may reduce complications. • Stop exercising immediately if you experience chest pain, fatigue, or labored breathing. • Avoid exercising in extreme weather conditions. • Drink plenty of water before, during, and after exercise. • Wear a medical identification bracelet, necklace, or ID tag in case of emergency. • Wear proper fitting shoes and socks, and check feet after exercise. STANDARD GUIDELINES F – 3-5 days a week. Include low weight resistance training 2 days/week I – 40-80% of exercise capacity using the heart rate reserve (HRR) (220-age=HRmax; HRmax-HRrest = HRR) T – 20-60mins/session, may start with sessions of 5-15 mins if necessary T – Large rhythmic muscle group activities that are low impact (walking, swimming, biking) Get wellness tips to keep YOU healthy at HENDRICKS.ORG/SOCIAL.. -
Bradycardias, Tachycardias and Other Heart Rhythm
BRADYCARDIAS, TACHYCARDIAS AND OTHER HEART RHYTHM DISTURBANCES BASIC ELECTROCARDIOGRAPHY JASSIN M. JOURIA, MD Dr. Jassin M. Jouria is a practicing Emergency Medicine physician, professor of academic medicine, and medical author. He graduated from Ross University School of Medicine and has completed his clinical clerkship training in various teaching hospitals throughout New York, including King’s County Hospital Center and Brookdale Medical Center, among others. Dr. Jouria has passed all USMLE medical board exams, and has served as a test prep tutor and instructor for Kaplan. He has developed several medical courses and curricula for a variety of educational institutions. Dr. Jouria has also served on multiple levels in the academic field including faculty member and Department Chair. Dr. Jouria continues to serve as a Subject Matter Expert for several continuing education organizations covering multiple basic medical sciences. He has also developed several continuing medical education courses covering various topics in clinical medicine. Recently, Dr. Jouria has been contracted by the University of Miami/Jackson Memorial Hospital’s Department of Surgery to develop an e-module training series for trauma patient management. Dr. Jouria is currently authoring an academic textbook on Human Anatomy & Physiology. ABSTRACT Electrocardiograms are valuable tests for evaluating heart health and to diagnose cardiac issues. But the test is only as good as the skill of the clinician performing it. Medical clinicians must commit to learning and updating their electrocardiogram procedure and interpretation skills to arrive at a correct diagnosis, and these skills start with an understanding of the basic function of the electrocardiogram. Being able to identify normal readings on an electrocardiogram rhythm strip is the first step to recognizing cardiac issues, and possibly saving lives. -
Basic Rhythm Recognition
Electrocardiographic Interpretation Basic Rhythm Recognition William Brady, MD Department of Emergency Medicine Cardiac Rhythms Anatomy of a Rhythm Strip A Review of the Electrical System Intrinsic Pacemakers Cells These cells have property known as “Automaticity”— means they can spontaneously depolarize. Sinus Node Primary pacemaker Fires at a rate of 60-100 bpm AV Junction Fires at a rate of 40-60 bpm Ventricular (Purkinje Fibers) Less than 40 bpm What’s Normal P Wave Atrial Depolarization PR Interval (Normal 0.12-0.20) Beginning of the P to onset of QRS QRS Ventricular Depolarization QRS Interval (Normal <0.10) Period (or length of time) it takes for the ventricles to depolarize The Key to Success… …A systematic approach! Rate Rhythm P Waves PR Interval P and QRS Correlation QRS Rate Pacemaker A rather ill patient……… Very apparent inferolateral STEMI……with less apparent complete heart block RATE . Fast vs Slow . QRS Width Narrow QRS Wide QRS Narrow QRS Wide QRS Tachycardia Tachycardia Bradycardia Bradycardia Regular Irregular Regular Irregular Sinus Brady Idioventricular A-Fib / Flutter Bradycardia w/ BBB Sinus Tach A-Fib VT PVT Junctional 2 AVB / II PSVT A-Flutter SVT aberrant A-Fib 1 AVB 3 AVB A-Flutter MAT 2 AVB / I or II PAT PAT 3 AVB ST PAC / PVC Stability Hypotension / hypoperfusion Altered mental status Chest pain – Coronary ischemic Dyspnea – Pulmonary edema Sinus Rhythm Sinus Rhythm P Wave PR Interval QRS Rate Rhythm Pacemaker Comment . Before . Constant, . Rate 60-100 . Regular . SA Node Upright in each QRS regular . Interval =/< leads I, II, . Look . Interval .12- .10 & III alike .20 Conduction Image reference: Cardionetics/ http://www.cardionetics.com/docs/healthcr/ecg/arrhy/0100_bd.htm Sinus Pause A delay of activation within the atria for a period between 1.7 and 3 seconds A palpitation is likely to be felt by the patient as the sinus beat following the pause may be a heavy beat. -
The Minnesota Code Classification System for Electrocardiographic
The Minnesota Code Classification System= for Electrocardiographic Findings Q and QS Patterns (Do not code in the presence of WPW code 6-4-1.) To qualify as a Q- or QS-wave, the deflection should be at least 0.1 mV (1 mm in amplitude). Anterolateral site (leads I, aVL, V6) 1-1-1 Q/R amplitude ratio ≥ 1/3, plus Q duration ≥ 0.03 sec in lead I or V6. 1-1-2 Q duration ≥ 0.04 sec in lead I or V6. 1-1-3 Q duration ≥ 0.04 sec, plus R amplitude ≥ 3 mm in lead aVL. 1-2-1 Q/R amplitude ratio ≥ 1/3, plus Q duration ≥ 0.02 sec and < 0.03 sec in lead I or V6. 1-2-2 Q duration ≥ 0.03 sec and < 0.04 sec in lead I or V6. 1-2-3 QS pattern in lead I. Do not code in the presence of 7-1-1. 1-2-8 Initial R amplitude decreasing to 2 mm or less in every beat (and absence of codes 3-2, 7-1-1, 7-2-1, or 7-3 between V5 and V6. (All beats in lead V5 must have an initial R > 2 mm.) 1-3-1 Q/R amplitude ratio ≥ 1/5 and < 1/3, plus Q duration ≥ 0.02 sec and < 0.03 sec in lead I or V6. 1-3-3 Q duration ≥ 0.03 sec and < 0.04 sec, plus R amplitude ≥ 3 mm in lead aVL. Posterior (inferior) site (leads II, III, aVF) 1-1-1 Q/R amplitude ratio ≥ 1/3, plus Q duration ≥ 0.03 sec in lead II. -
Cardiovascular Disease Session Guidelines
Cardiovascular Disease Session Guidelines This is a 15 minute webinar session for CNC physicians and staff CNC holds webinars on the 3rd Wednesday of each month to address topics related to risk adjustment documentation and coding Next scheduled webinar: • Wednesday, February 28th • Topic: Respiratory Disease CNC does not accept responsibility or liability for any adverse outcome from this training for any reason including undetected inaccuracy, opinion, and analysis that might prove erroneous or amended, or the coder/physician’s misunderstanding or misapplication of topics. Application of the information in this training does not imply or guarantee claims payment. Agenda • Statistics • Amputation Status & Atherosclerosis • Angina Pectoris • Acute Myocardial Infarction • Specified Heart Arrhythmias • Congestive Heart Failure • Pulmonary Hypertension • Cardiomyopathy • Hypertensive Heart disease Statistics • Nearly 35 percent of Tarrant County and Dallas area deaths each year are attributed to cardiovascular disease. • About 610,000 people die of heart disease in the United States every year–that’s 1 in every 4 deaths • Heart disease is the leading cause of death for both men and women • Every year about 735,000 Americans have a heart attack. Of these, (approximately 70%) 525,000 are a first heart attack and (approximately 30%)210,000 happen in people who have already had a heart attack Amputations There are nearly 2 million people living with limb loss in the United States Approximately 185,000 amputations occur in the United States each -
Case Report: Cytarabine-Induced Pericarditis and Pericardial Effusion Rino Sato, MD and Robert Park, MD
HEMATOLOGY & ONCOLOGY Case Report: Cytarabine-Induced Pericarditis and Pericardial Effusion Rino Sato, MD and Robert Park, MD INTRODUCTION for inpatient chemotherapy, and demonstrated mild global left ventricular dysfunction with ejection fraction Cytarabine (cytosine arabinoside, Ara-C) is an antime- of 40%. The cardiomyopathy was attributed to his tabolite analogue of cytidine that is used as a chemo- underlying hypertension or sleep apnea, and not therapeutic agent for the treatment of acute myelogenous coronary artery disease based on a normal coronary leukemia and lymphocytic leukemias1 . The most computed tomography (CT) angiogram. The patient common side effects of this therapy include myelosup- was started on induction therapy with high-dose pression, pancytopenia, hepatotoxicity, gastrointestinal cytarabine therapy at 3g/m2 every twelve hours without ulceration with bleeding, and pulmonary infiltrates2. an anthracycline agent such as doxorubicin. Cardio-pulmonary complications of cytarabine therapy are uncommon, but include supraventricular and On day 5 of cytarabine therapy, the patient developed ventricular arrhythmias, sinus bradycardia, and recurrent non-radiating sharp chest pain that worsened with heart failure2, 3. Occasionally, patients may develop inspiration and palpation. He had no cough or sputum pericarditis leading to pericardial tamponade, which can production. His cardiac exam revealed a tri-phasic, be fatal. We report a case of cytarabine-induced high-pitched friction rub best heard over the left lower pericarditis and pericardial effusion to increase awareness sternal border. He was normotensive, did not have pulsus about this serious side effect of cytarabine and review paradoxus, and had minimally distended jugular veins. the current literature. An electrocardiogram revealed widespread concave ST-elevation and PR-depression in the limb leads (I, II, III, CASE PRESENTATION avF) and precordial leads (V5-V6) concerning for acute pericarditis (Figure 1). -
Natural History Following Ventricular Pacemaker Implantation
Symptomatic Brady arrhythmias in the Adult: Natural History Following Ventricular Pacemaker Implantation ARTHUR B. SIMON and NANCY JANZ From the Departments of Internal Medicine, Division of Cardiology and Nursing Services of the University of Michigan Medical Center, Ann Arbor, Michigan SIMON, A.B., AND JANZ, N.: Symptomatic bradyarrhythmias in the adult: natural history following ventricular pacemaker impiantation. The preimplantation arrhythmias, coexistent medical condi- tions, the causes of death, and survival course are described for 399 patients who received their initial ventricuJar pacemaker impiantation for a bradyarrhythmia (AV block, sinus node disease, and hyper- sensitjVe carotid sinus syndrome] at the (Jniversity of Michigan from 1961 to 1979. Factors which corre- lated with a poor survival are elucidated. Survival for those with sinus node disease was virtually identi:;al to those with AV block, with only 63% surviving over jive years. Advanced age and conges- tive heart failure prior to implantation, and underlying ischemic or hypertensive heart disease por- tended a poorer survival in both groups. Patients with hypersensitive carotid sinus syndrome had a distinctly better prognosis—no deaths occurred until (he eighth year after pacing. Patients with no underlying heart disease and those with valvular disease did remarkably better than those with an ischemic or myopathic etiology. Apparent progression or complications of the underlying heart dis- ease v/as the major cause of mortality. Sudden death, congestive heart failure, myocardial infarction, and major arrhythmias were the causes of death in 48% of those who died. Implications of improved pacing modalities an late complications and death are discussed. (PACE, Vol. 5, iVlay-June, 1982] bradyarrhythmias, ventricular pacemaker For nearly two decades permanenl pacemakers processor technology, have resulted in smaller, have been the treatment of choice for high longer lasting, and improved pacing devices.